The Impact of Migrations on the Health Services for Rare Diseases in Europe: The Example of Haemoglobin Disorders
Table 1
Estimations of the number of carriers in the countries studied.
Country
Total population
Total number of immigrants carriers of -thalassaemia
Total number of carriers of b-thalassaemia in the indigenous population
Total number of immigrant carriers of HbE
Total number of immigrants carries of sickle cell
Total number of immigrant carriers of HbC
Carrier immigrants as a proportion of the total population
Carriers of Hb disorders as a proportion of the total population
(1) Austria
8210281
11842
8210
2453
4675
708
0.24%
0.34%
(2) Belgium
10438353
19403
10438
4073
39250
5169
0.65%
0.75%
(3) Cyprus
840407
3991
121019
354
583
20
0.58%
15%
(4) Denmark
5543453
6772
5543
4083
2277
330
0.24%
0.34%
(5) France
64057792
98219
64058
32607
172600
47884
0.54%
0.65%
(6) Germany
82329758
128419
82330
22955
53883
7135
0.25%
0.36%
(7) Greece
10737429
29289
837519
536
7626
183
0.35%
8.70%
(8) Italy
61261254
75748
2572972
9463
72870
21416
0.29%
6.50%
(9) The Netherlands
16715999
27656
16716
13751
30329
7703
0.47%
0.57%
(10) Spain
47042984
57257
715053
2434
92601
27796
0.38%
1.90%
(11) Sweden
9482855
21092
9483
12593
8720
912
0.46%
0.56%
(12) UK
63047162
107694
63047
27124
145038
25290
0.48%
0.58%
These results are the nearest figures that are calculated on the available data on immigrant populations. It was assumed that Northern European populations have a thalassaemia carrier rate of 0.1% in their indigenous populations and no carriers of the sickle cell gene. The importance is that in the countries where the prevalence is high in the indigenous population (Italy, Greece, and Cyprus), there are national policies to meet the needs of these disorders. In the rest of Europe the proportion of immigrants is approximately similar, yet only the UK and France have disease specific policies. The carrier frequency is rising most rapidly in Belgium and Spain where national planning is most urgently needed.